Clinical Report: Procedural Pharmaceutical Lessons From Early Adopters
Overview
Experienced glaucoma surgeons provide insights on integrating sustained drug delivery systems into glaucoma management. Two FDA-approved options, Durysta and iDose TR, offer alternatives to daily topical therapies.
Background
Sustained-release drug delivery systems represent a significant advancement in glaucoma management, addressing challenges associated with daily topical medication adherence. Understanding how to effectively incorporate these options into clinical practice is essential for optimizing glaucoma care.
Data Highlights
No numerical or trial data provided in the source material.
Key Findings
Durysta and iDose TR are FDA-approved for reducing intraocular pressure in open-angle glaucoma.
Patient education on non-topical options can significantly influence treatment preferences.
Surgeons emphasize the importance of individualized treatment plans.
Effective communication about the benefits of sustained drug delivery can enhance patient acceptance.
Both implants provide a long-term solution for medication management.
Clinical Implications
Surgeons should consider sustained-release options as part of glaucoma management.
Conclusion
The integration of sustained drug delivery systems into glaucoma management emphasizes personalized care.
Is There a Role for SLT After MIGS? A practical framework for patient selection and clinical decision-making when intraocular pressure rises after minimally invasive glaucoma surgery.
